Thank you to all the delegates who attended the FT Global Pharmaceutical & Biotechnology Conference 2012, Europe's pre-eminent industry event attended by over 300 delegates over 2 insightful days of discussion between leading industry executives, government decision makers, investors, analysts and other specialist providers.
The Conference explored the key issues facing the global life science industry, including the transition to value based pricing and the demands of real world evidence, and how forward looking companies are refining their strategies, building capabilities and transforming their operating models to stay ahead of the game.
In Association with:
Franz Humer Chairman of the Board Roche
Joaquin Duato Worldwide Chairman, Pharmaceuticals Johnson & Johnson
Lord Sebastian Coe Chair, LOCOG
Chairman, Research & Development, GlaxoSmithKline
Vice President, Head of R&D for Asia and Emerging Markets, AstraZeneca
Additional speakers included
Trevor Mundel, President, Global Health Program, Bill & Melinda Gates Foundation John Dineen, President and CEO, GE Healthcare Jorge Gallardo Ballart, Chairman, Almirall David Reddy, CEO, Medicines for Malaria Venture (MMV) Frank Morich, Director and Chief Commercial Officer, Takeda International Peter Greenleaf, President, Medlmmune Duncan Learmouth, Senior Vice President, Developing Countries and Market Access, GlaxoSmithKline Professor Sir Michael Rawlins, Chairman, Institute for Health and Clinical Excellence
Neil de Crescenzo, Senior Vice President and General Manager, Health Sciences Global Business Unit, Oracle